COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countriesEng Hooi Tan, Daniel Prieto‐Alhambra, Anthony G. Sena et al.|Lara D. Veeken|2021Cited by 53
Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort studyErica A. Voss, Rohit Vashisht, Azza Shoaibi et al.|EClinicalMedicine|2023Cited by 27
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Nicole G. Weiskopf, Talita Duarte‐Salles et al.|Clinical Epidemiology|2022Cited by 26
A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest GroupRachel Black, Catherine Hill, Joanna Robson et al.|The Journal of Rheumatology|2017Cited by 22
Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological DesignsMartijn J. Schuemie, Marc A. Suchard, Faaizah Arshad et al.|Frontiers in Pharmacology|2022Cited by 19